Oxonol vs MIT Tablets: Product Identity, Form and Documents
Oxonol tablets and MIT tablets may share a chewable form, but their stated ingredient identities are different. The Oxonol manufacturer describes its formula as MGM-15 plus mitragynine. Kratom Paradise MIT tablets are presented around mitragynine and are not marketed as MGM-15 products.
Start with the ingredient, not the tablet shape
A chewable tablet is a delivery format. It does not establish whether the tablet contains MIT, MGM-15, 7-OH, pseudoindoxyl, or a blend. Flavor and tablet count can be compared only after the active ingredient and unit basis are clear.
| Term | What it identifies | July 2026 federal record |
|---|---|---|
| Oxonol | A commercial brand/product-line name. Its manufacturer describes the tablets as containing MGM-15 plus mitragynine. | The brand name is not listed in DEA's notice; the named ingredient MGM-15 is. |
| MGM-15 | Dihydro-7-hydroxymitragynine, a synthetic derivative of 7-hydroxymitragynine. | Named in DEA's July 6 notice of intent for temporary Schedule I placement. |
| 7-OH | 7-hydroxymitragynine, which can occur at trace levels in botanical material and also appears in elevated or synthesized commercial products. | Covered by a separate July 2026 DEA notice with specified concentration thresholds. |
| MIT | Mitragynine, a naturally occurring alkaloid of Mitragyna speciosa. MIT extracts concentrate that named alkaloid. | Not one of the three MGM/pseudoindoxyl substances named in the MGM-15 notice. |
Oxonol's stated product identity
The manufacturer calls Oxonol a brand name and currently describes the chewable tablets as containing MGM-15 and mitragynine. DEA identifies MGM-15 as dihydro-7-hydroxymitragynine, a synthetic derivative of 7-hydroxymitragynine. Because formulas can change, the current label and manufacturer page remain the starting evidence.
Kratom Paradise MIT tablet identity
MIT is mitragynine, a naturally occurring kratom alkaloid. Kratom Paradise’s current MIT tablet pages state the labeled MIT option, flavor, and count. They also explain that the current tablets are made from the 90% MIT-CH concentrate associated with a source-material report. That report covers the submitted concentrate, not the finished tablets, and the listing preserves that limit.
This is a narrower claim than calling the finished tablet lab tested or certified. It gives buyers a traceable source-material relationship without implying that a concentrate report automatically becomes a finished-product COA.
Why MIT is the clearer lane for some buyers
For a buyer who wants a single familiar alkaloid name, a tablet or powder choice, explicit selector fields, and qualified documentation, MIT is easier to evaluate. It is not another retail name for MGM-15 and it is not positioned as a synthetic 7-OH replacement. The comparison rests on identity and records rather than promises about effects.
Regulatory comparison
DEA’s July 2026 notice expressly names MGM-15 and says a temporary Schedule I order will not issue before August 5, 2026. MIT is not one of the three substances named in that notice. However, state and local rules can use broader definitions or product thresholds. Neither a brand name nor an online “legal” claim replaces a jurisdiction-specific check.
Tablet fields to compare side by side
- Named ingredients: MIT only, MGM-15 plus MIT, 7-OH, or another mixture.
- Amount basis: per tablet, per serving, per package, or percentage.
- Count: the number of tablets in the package.
- Documents: source material versus finished product, with sample and date.
- Formula date: whether the current listing matches the package being purchased.
- Regulatory date: whether a statement predates the July 2026 notice or a later order.
What this comparison does not establish
It does not establish equivalent effects, relative safety, medical usefulness, a withdrawal strategy, or universal legality. FDA has not approved 7-OH products, and a different brand or ingredient is not thereby FDA approved. Product identity and documentation can support a careful comparison, but they do not turn a retail product into a medicine.
Continue the comparison
Read the full comparison page, review the MIT documents center, or compare standard MIT tablets and bulk MIT tablets.
Kratom Paradise does not sell Oxonol or MGM-15 products. This article is educational product and regulatory information, not medical or legal advice.